retatrutide trials in boston Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Eli Lilly touts strong results

[1] These medications work by mimicking the action of naturally occurring GLP-1, an incretin hormone that stimulates insulin secretion in response to food intake, suppresses glucagon release, slows gastric emptying, and promotes satiety through central nervous system pathways

No drama, no discomfort, just fiber quietly doing its thing

Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus

Previous studies have estimated that the economic burden of sarcopenia in the United States accounts for approximately 1.5% of total national health expenditures [7], with annual per capita healthcare costs rising by $2,315.7 in individuals with sarcopenia [8]

Inquire whether your treatment plan includes structured support for diet, exercise, and behavioral change